Primary tabs

Other Access

The information on this page (the dataset metadata) is also available in these formats.

JSON RDF

via the DKAN API

A Phase 1b2 Trial of AMG 386 in Combination With Pemetrexed and Carboplatin as First Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer

laboratory abnormalities defined as dose-limiting toxicity in subjects with metastatic non-squamous nonsmall cell lung cancer NSCLC treated with AMG 386 in combination with pemetrexed and carboplatin Part 2: To estimate the treatment effect of AMG 386 as measured by progression free survival PFS of AMG 386 versus AMG 386 placebo in combination with pemetrexed and carboplatin induction therapy followed by pemetrexed and AMG 386 or AMG 386 placebo as maintenance therapy in subjects with metastatic non-squamous NSCLC

FieldValue
Modified
2020-03-11
Release Date
2018-07-09
Identifier
a19013c8-8ba6-4988-83f9-c9deeb4b815a
License
Public Access Level
Public